A Free--or Freer--Hand in Corporate VC
This article was originally published in Start Up
Executive Summary
If pure-play pharmaceutical businesses, with resulting de-mergers and spin-offs as the tools of choice, is the new name of the health care game, Novo Nordisk is becoming a master. The recent reorganization of the Danish pharmaceutical company gives each of its separate businesses the operating freedom to do what it does best. It creates perhaps the most unusual corporate venture capital group in the industry.